HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that it has entered into laboratory service and assay development agreements with Merck Serono, Geneva, Switzerland, a division of Merck KGaA, Darmstadt, Germany. The agreements cover laboratory service testing and development of specialized biomarker assays based on Circulating Tumor Cells (CTCs), within the scope of an early clinical drug study. With the results of the tests performed within the scope of the agreements, researchers at Merck Serono may be able to examine biological activity of the drug(s) being evaluated, both early in the course of treatment and early in the drug development process. Moreover, the new assays developed under the agreement may eventually help doctors to identify patients who have a high probability of responding to the drug under investigation.
Leon Terstappen, M.D. PhD, Chief Scientific Officer of Immunicon, said, “We are looking forward to starting this collaboration with Merck Serono. The ability to ‘interrogate’ the extremely rare circulating cells once isolated from peripheral blood gives unprecedented opportunities to see ‘real-time’ what is happening with tumor cells in patients upon exposure to investigational drugs. On top of testing kinetics of circulating tumor cells, which may give important information on drug activity itself, the assays we will be developing in this project may provide predictive information as to who is likely to react to the drug and who is not. This can ultimately be an important tool on the way to personalizing cancer therapy.”
Byron D. Hewett, President and Chief Executive Officer of Immunicon, commented, “We are very pleased to work with Merck Serono, a global company focusing on innovative small molecules and biopharmaceuticals. The laboratory service testing and the specialized assay we will develop is yet another example of the value of rare cell isolation and analysis in oncology drug development studies.”
About Immunicon Corporation
Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management. Immunicon has developed platform technologies for selection and analysis of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in the clinical development of cancer drugs and in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as “hope,” “may,” “believe,” “anticipate,” “plan,” “expect,” “intend,” “assume,” “will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements regarding the anticipated clinical utility of Immunicon’s products and services and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, are based on the current expectations and intent of the management of Immunicon and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by these statements. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, including, but not limited to, risks and uncertainties associated with: Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of product candidates; Immunicon’s ability to obtain licenses from third parties to commercialize products; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers; compliance with applicable manufacturing standards; retaining key personnel; delays in the development of new products or planned improvements to products; effectiveness of products compared to competitors’ products; protection of Immunicon’s intellectual property; conflicts with third party intellectual property; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. Except as required by law, Immunicon accepts no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for modifications made to this document by Internet or wire services.
“Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ALL RIGHTS RESERVED.
Contact:
Immunicon Corporation James G. Murphy SVP of Finance & Administration, CFO 215-346-8313 jmurphy@immunicon.com or
Investors/Media: Tierney Communications Denise Portner Vice President 215-790-4395 dportner@tierneyagency.com
Source: Immunicon Corporation
